REGENXBIO’s $1.8 Billion Partnership With AbbVie

McDermott Will & Emery represented REGENXBIO in the transaction.REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time gene…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here